AMAALA
9.6.2020 10:02:13 CEST | Business Wire | Press release
AMAALA, the ultra-luxury destination located along Saudi Arabia’s northwestern coast, appointed Saudi Arabian Parsons Limited (Parsons), who, following a competitive tender, was awarded the construction supervision contract. The digitally enabled solutions provider is taking on the role of engineer, supervising the execution of works currently underway across Phase I of Triple Bay.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200609005322/en/
Binyah, a Saudi Real Estate Infrastructure Company, joins Parsons onsite carrying out the excavation, backfilling, and earthworks required to achieve the formation levels and grading of Phase I of the Triple Bay masterplan.
Chief Executive Officer of AMAALA, Nicholas Naples said: "We are delighted to work with two prestigious firms on a project of this scale. We are very pleased with the progress to date and have welcomed the expertise and experience both Parsons and Binyah have brought to the development of the destination. We celebrated a milestone moment in our history when work onsite began, and we are looking forward to working closely together to bring our vision for Triple Bay to life. Together we will deliver an ultra-luxury destination for future generations around the globe, nested in the long-term vision of the Kingdom of Saudi Arabia."
AMAALA’s environmental team is guiding Parsons and Binyah on the AMAALA site to oversee all stages of development, ensuring work is being carried out within its sustainability and environmental guidelines.
Commenting on the signing, Managing Director of Saudi Arabian Parsons Limited, Ken Murray, said: "As an iconic development in the Kingdom, AMAALA is set to become a preeminent destination for travellers from the world over. Parsons is thrilled to join the delivery team, and we look forward to supporting the Triple Bay development and continue our proud participation in the delivery of Vision 2030 for Saudi Arabia."
Chief Executive Officer of Binyah, Eng. Fahad Al-Mesfir stated: "The agreement marked a strategic turning point for the company, given it’s the first business agreement with AMAALA to implement the preparatory works. Binyah is working to provide the highest quality standards in the implementation of the project, which will contribute to achieving the ambitions of the Kingdom’s 2030 vision."
Set in the Prince Mohammed bin Salman Nature Reserve across three unique communities, AMAALA will bring to life the desires and ambitions of a community passionate about shaping and living transformative moments. AMAALA’s trio of communities – Triple Bay, The Coastal Development, and The Island – will showcase three different sets of experiences for guests.
- Triple Bay will offer a fully holistic wellness retreat, state-of-the-art diagnostic medical facilities and authentic treatments designed to feature the local environment. Triple Bay will also be home to a fully integrated sports and entertainment community.
- The Costal Development is set to become the defining hub of contemporary art in the Middle East, playing host to a dynamic programme of exciting events from the global arts and cultural calendar.
- The Island will be the tranquil home of an exclusive art community, and an Arabic botanical garden bestrewn with sculptural pieces.
With a focus on creating transformative personal journeys inspired by arts, wellness and the purity of the Red Sea, AMAALA will allow travellers to immerse themselves in the finest wellness, arts, culture, sports and fitness offerings, redefining the luxury tourism experience.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20200609005322/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
